JP2007502820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502820A5 JP2007502820A5 JP2006523954A JP2006523954A JP2007502820A5 JP 2007502820 A5 JP2007502820 A5 JP 2007502820A5 JP 2006523954 A JP2006523954 A JP 2006523954A JP 2006523954 A JP2006523954 A JP 2006523954A JP 2007502820 A5 JP2007502820 A5 JP 2007502820A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- benzimidazole
- carboxamide
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 230000003463 hyperproliferative Effects 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- -1 3,5-dimethoxyphenyl Chemical group 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000009030 carcinoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- UPQTXQWNEOLBOJ-UHFFFAOYSA-N 1-(3-fluorophenyl)-N-(2-methyl-5-phenylpyrazol-3-yl)benzimidazole-5-carboxamide Chemical compound CN1N=C(C=2C=CC=CC=2)C=C1NC(=O)C(C=C1N=C2)=CC=C1N2C1=CC=CC(F)=C1 UPQTXQWNEOLBOJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 208000002517 Adenoid Cystic Carcinoma Diseases 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000003076 angiosarcoma Diseases 0.000 claims 1
- 230000001772 anti-angiogenic Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 230000002147 killing Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005161 thyroid carcinoma Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (16)
- 式(I):
R11は、F、Cl、C0−8アルキル、C0−8アルコキシまたは−N(C0−8アルキル)(C0−8アルキル)であり;
R51は、1から5個の独立したハロゲン、−NR34R35、−NR34COR35、−NR34C(O)OR35、−NR34SO2R35、−OR34、−SR34、−SO2R34、−SO2NR34R35、−C(O)OR34、−CO2H、−CONR34R35、C0−8アルキル、C2−8アルケニル、C2−8アルキニル、CN、CF3、NO2、オキソ、シクリルまたはヘテロシクリル置換基で場合により置換されているフェニルであり;
R52は、ハロゲン、CF3、−CN、C0−8アルキル、C0−8アルコキシ、−COOH、または−N(C0−8アルキル)(C0−8アルキル)であり;
Xは、1から4個の独立したF、Cl、CF3、−CN、C0−8アルキル、C0−8アルコキシ、−COOHまたは−N(C0−8アルキル)(C0−8アルキル)置換基で場合により置換されている、シクリルまたはヘテロシクリル基であり;
R34およびR35は、独立して、ヘテロシクリルもしくはOH置換基で場合により置換されているC0−8アルキル;−C0−8アルキル−C3−8シクロアルキル、CF3、−C0−8アルキル−O−C0−8アルキル、−C0−8アルキル−N(C0−8アルキル)(C0−8アルキル)、−C0−8アルキル−S(O)0−2−C0−8アルキルまたはC0−8アルキル、シクリルもしくは置換シクリル置換基で場合により置換されているヘテロシクリルである。)
によって表される化合物またはこの医薬適合性の塩もしくはN−オキシド。 - Xが、場合により置換されているシクリルである、請求項1に記載の化合物またはこの医薬適合性の塩もしくはN−オキシド。
- Xが、場合により置換されているフェニルである、請求項2に記載の化合物またはこの医薬適合性の塩もしくはN−オキシド。
- 請求項1に記載の化合物またはこの医薬適合性の塩もしくはN−オキシドおよび医薬適合性担体を含む組成物。
- 請求項1に記載の化合物またはこの医薬適合性の塩もしくはN−オキシドおよび抗新生物薬、抗腫瘍薬、抗血管新生薬または化学療法薬を含む組成物。
- 請求項1に記載の化合物またはこの医薬適合性の塩もしくはN−オキシドおよび細胞障害性癌治療薬を含む組成物。
- 請求項1に記載の化合物またはこの医薬適合性の塩もしくはN−オキシドおよび血管新生阻害性癌治療薬を含む組成物。
- 1−(3−フルオロフェニル)−N−[3(5)−フェニルピラゾール−5(3)−イル]−1H−ベンズイミダゾール−5−カルボキサミド;
1−(3−フルオロフェニル)−N−[3(5)−(4−クロロフェニル)ピラゾール−5(3)−イル]−1H−ベンズイミダゾール−5−カルボキサミド;
1−(3−フルオロフェニル)−N−[3(5)−p−トリルピラゾール−5(3)−イル]−1H−ベンズイミダゾール−5−カルボキサミド;
1−(3−フルオロフェニル)−N−(1−メチル−3−フェニルピラゾール−5−イル)−1H−ベンズイミダゾール−5−カルボキサミド;
1−(4−メトキシフェニル)−N−(3(5)−フェニルピラゾール−5(3)−イル)−1H−ベンズイミダゾール−5−カルボキサミド;
1−[3−メトキシ−5−(トリフルオロメチル)フェニル]−N−(3(5)−フェニルピラゾール−5(3)−イル)−1H−ベンズイミダゾール−5−カルボキサミド;
1−(3,5−ジメトキシフェニル)−N−(3(5)−フェニルピラゾール−5(3)−イル)−1H−ベンズイミダゾール−5−カルボキサミド;
1−(3−イソプロポキシフェニル)−N−(3(5)−フェニルピラゾール−5(3)−イル)−1H−ベンズイミダゾール−5−カルボキサミド;
1−(4−ブロモフェニル)−N−(3(5)−フェニルピラゾール−5(3)−イル)−1H−ベンズイミダゾール−5−カルボキサミド
から成る化合物またはこの医薬適合性の塩もしくはN−オキシド。 - 請求項1に記載の化合物の有効量を投与する段階を含む、高増殖性疾患の治療方法。
- 抗新生物薬、抗腫瘍薬、抗血管新生薬または化学療法薬を投与する段階をさらに含む、請求項9に記載の方法。
- 前記高増殖性疾患が、乳癌、頭部癌または頚部癌である、請求項9に記載の方法。
- 前記高増殖性疾患が、胃腸癌である、請求項9に記載の方法。
- 前記高増殖性疾患が、白血病である、請求項9に記載の方法。
- 前記高増殖性疾患が、卵巣癌、気管支癌、肺癌または膵臓癌である、請求項9に記載の方法。
- 前記高増殖性疾患が、小細胞肺癌または大腸癌である、請求項9に記載の方法。
- 前記高増殖性疾患が、副鼻腔(sinonasal)ナチュラルキラー/T細胞リンパ腫、精巣癌(精上皮腫)、甲状腺癌腫、悪性黒色腫、腺様嚢胞癌腫、血管肉腫、未分化大細胞リンパ腫、子宮内膜癌腫または前立腺癌腫である、請求項9に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49676603P | 2003-08-21 | 2003-08-21 | |
US60/496,766 | 2003-08-21 | ||
PCT/US2004/026481 WO2005021537A1 (en) | 2003-08-21 | 2004-08-16 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007502820A JP2007502820A (ja) | 2007-02-15 |
JP2007502820A5 true JP2007502820A5 (ja) | 2007-10-04 |
JP4795237B2 JP4795237B2 (ja) | 2011-10-19 |
Family
ID=34272512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006523954A Expired - Fee Related JP4795237B2 (ja) | 2003-08-21 | 2004-08-16 | N−置換ピラゾリル−アミジル−ベンズイミダゾリルc−Kit阻害剤 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1664032B1 (ja) |
JP (1) | JP4795237B2 (ja) |
KR (1) | KR20060115346A (ja) |
CN (1) | CN1839130A (ja) |
AP (1) | AP2006003553A0 (ja) |
AR (1) | AR045389A1 (ja) |
AT (1) | ATE413395T1 (ja) |
AU (1) | AU2004268948A1 (ja) |
BR (1) | BRPI0413785A (ja) |
CA (1) | CA2536151A1 (ja) |
DE (1) | DE602004017623D1 (ja) |
IL (1) | IL173616A0 (ja) |
IS (1) | IS8320A (ja) |
MX (1) | MXPA06002017A (ja) |
NO (1) | NO20060665L (ja) |
RU (1) | RU2006108791A (ja) |
TW (1) | TW200524911A (ja) |
UA (1) | UA84712C2 (ja) |
WO (1) | WO2005021537A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
CN101316590B (zh) | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
WO2007083904A1 (en) * | 2006-01-18 | 2007-07-26 | Lg Household & Health Care Ltd. | C-kit activation inhibitor, skin whitening compound and composition for skin whitening containing the same |
TW200740776A (en) * | 2006-02-06 | 2007-11-01 | Osi Pharm Inc | N-phenylbenzotriazolyl c-kit inhibitors |
US20090209580A1 (en) * | 2006-05-18 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
WO2012121168A1 (ja) * | 2011-03-04 | 2012-09-13 | 国立大学法人京都大学 | キナーゼ阻害剤 |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
TW201534597A (zh) * | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
KR102512940B1 (ko) | 2014-08-28 | 2023-03-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
JP6792546B2 (ja) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
GB8610980D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Heterocyclic fused tricyclic compounds |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
NZ276172A (en) | 1994-02-10 | 1998-02-26 | Pfizer | 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists, 5-(hetero)arylaminoindole intermediates |
US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
PT846689E (pt) | 1996-12-09 | 2004-06-30 | Pfizer | Compostos de benzimidazole |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
EP0995742A4 (en) | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE |
US5990146A (en) * | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2000012089A1 (en) | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
CA2338827A1 (en) | 1998-07-28 | 2000-02-10 | Hideo Takaishi | Fused heterocyclic dicarboxylic acids diamide derivatives or salts thereof, herbicide and method for using the same |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
US6348032B1 (en) * | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
US6329383B1 (en) | 1999-01-25 | 2001-12-11 | Pharmacia Ab | 2-amino-5-pyrimidine acetic acid compounds |
AU3931400A (en) | 1999-04-02 | 2000-10-23 | Neurogen Corporation | N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators |
CO5190696A1 (es) | 1999-06-16 | 2002-08-29 | Smithkline Beecham Corp | Antagonistas de los receptores il-8 |
WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
DE19939463A1 (de) | 1999-08-20 | 2001-02-22 | Boehringer Ingelheim Pharma | Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE60016858T2 (de) | 1999-09-13 | 2005-12-08 | Eastman Kodak Co. | Photographisches Material mit verbesserter Farbwiedergabe |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
WO2001057020A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
WO2001057019A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
WO2002030886A2 (en) | 2000-10-12 | 2002-04-18 | Matthews Barry R | Heterocyclic angiogenesis inhibitors |
WO2002083143A1 (en) | 2000-12-11 | 2002-10-24 | Tularik Inc. | Cxcr3 antagonists |
GB0102109D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
EP1387680A4 (en) | 2001-03-05 | 2010-01-13 | Transtech Pharma Inc | AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE |
PL364230A1 (en) | 2001-03-12 | 2004-12-13 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
US20030009034A1 (en) | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
-
2004
- 2004-08-16 BR BRPI0413785-0A patent/BRPI0413785A/pt not_active IP Right Cessation
- 2004-08-16 AT AT04781203T patent/ATE413395T1/de not_active IP Right Cessation
- 2004-08-16 DE DE602004017623T patent/DE602004017623D1/de active Active
- 2004-08-16 KR KR1020067003094A patent/KR20060115346A/ko not_active Application Discontinuation
- 2004-08-16 AU AU2004268948A patent/AU2004268948A1/en not_active Abandoned
- 2004-08-16 MX MXPA06002017A patent/MXPA06002017A/es unknown
- 2004-08-16 CN CNA2004800239977A patent/CN1839130A/zh active Pending
- 2004-08-16 WO PCT/US2004/026481 patent/WO2005021537A1/en active Application Filing
- 2004-08-16 UA UAA200602943A patent/UA84712C2/ru unknown
- 2004-08-16 RU RU2006108791/04A patent/RU2006108791A/ru not_active Application Discontinuation
- 2004-08-16 AP AP2006003553A patent/AP2006003553A0/xx unknown
- 2004-08-16 JP JP2006523954A patent/JP4795237B2/ja not_active Expired - Fee Related
- 2004-08-16 EP EP04781203A patent/EP1664032B1/en active Active
- 2004-08-16 CA CA002536151A patent/CA2536151A1/en not_active Abandoned
- 2004-08-20 AR ARP040103010A patent/AR045389A1/es not_active Application Discontinuation
- 2004-08-20 TW TW093125240A patent/TW200524911A/zh unknown
-
2006
- 2006-02-08 IL IL173616A patent/IL173616A0/en unknown
- 2006-02-10 NO NO20060665A patent/NO20060665L/no not_active Application Discontinuation
- 2006-02-21 IS IS8320A patent/IS8320A/is unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007502820A5 (ja) | ||
RU2006108791A (ru) | N-замещенные пиразолиламидилбензимидазолилы в качестве с-kit ингибиторов | |
JP2010525056A5 (ja) | ||
JP2015517566A5 (ja) | ||
RU2018110770A (ru) | Ингибиторы mdm2 и их комбинации | |
JP2014526549A5 (ja) | ||
JP2017008088A5 (ja) | ||
JP2009514870A5 (ja) | ||
JP2009501745A5 (ja) | ||
JP2009526072A5 (ja) | ||
JP2011509309A5 (ja) | ||
RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
JP2013510120A5 (ja) | ||
JP2010526814A5 (ja) | ||
JP2014525454A5 (ja) | ||
JP2017519019A5 (ja) | ||
JP2005533748A5 (ja) | ||
JP2014532070A5 (ja) | ||
JP2014532647A5 (ja) | ||
RU2014112198A (ru) | Синергические композиции ингибиторов pi3k и мек | |
JP2017528475A5 (ja) | ||
JP2015529194A5 (ja) | ||
JP2013504536A5 (ja) | ||
JP2019528307A5 (ja) | ||
JP2008519049A5 (ja) |